JP2009513669A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009513669A5 JP2009513669A5 JP2008538048A JP2008538048A JP2009513669A5 JP 2009513669 A5 JP2009513669 A5 JP 2009513669A5 JP 2008538048 A JP2008538048 A JP 2008538048A JP 2008538048 A JP2008538048 A JP 2008538048A JP 2009513669 A5 JP2009513669 A5 JP 2009513669A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- matrix
- drugs
- rate regulating
- hydrogel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011159 matrix material Substances 0.000 claims 27
- 230000004888 barrier function Effects 0.000 claims 8
- 230000001105 regulatory effect Effects 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 239000000463 material Substances 0.000 claims 6
- 239000002775 capsule Substances 0.000 claims 5
- 239000000032 diagnostic agent Substances 0.000 claims 5
- 229940039227 diagnostic agent Drugs 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000000069 prophylactic effect Effects 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 229940125714 antidiarrheal agent Drugs 0.000 claims 2
- 239000003793 antidiarrheal agent Substances 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 230000009977 dual effect Effects 0.000 claims 2
- 239000007903 gelatin capsule Substances 0.000 claims 2
- -1 polyoxyethylene Polymers 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229920001007 Nylon 4 Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 239000002269 analeptic agent Substances 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000004004 anti-anginal agent Substances 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000002421 anti-septic effect Effects 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 229940124346 antiarthritic agent Drugs 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 229940125681 anticonvulsant agent Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000002282 antimigraine agent Substances 0.000 claims 1
- 229940125684 antimigraine agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940125687 antiparasitic agent Drugs 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 239000000939 antiparkinson agent Substances 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- 229940125716 antipyretic agent Drugs 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 229940121383 antituberculosis agent Drugs 0.000 claims 1
- 239000003699 antiulcer agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000002830 appetite depressant Substances 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 230000002051 biphasic effect Effects 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 229940105329 carboxymethylcellulose Drugs 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 229920001525 carrageenan Polymers 0.000 claims 1
- 229940113118 carrageenan Drugs 0.000 claims 1
- 229920003086 cellulose ether Polymers 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 229920000591 gum Polymers 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 239000003326 hypnotic agent Substances 0.000 claims 1
- 230000000147 hypnotic effect Effects 0.000 claims 1
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 239000003887 narcotic antagonist Substances 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 230000001734 parasympathetic effect Effects 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000003368 psychostimulant agent Substances 0.000 claims 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims 1
- 230000000580 secretagogue effect Effects 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229940127230 sympathomimetic drug Drugs 0.000 claims 1
- 229940125725 tranquilizer Drugs 0.000 claims 1
- 239000003204 tranquilizing agent Substances 0.000 claims 1
- 230000002936 tranquilizing effect Effects 0.000 claims 1
- 239000000814 tuberculostatic agent Substances 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73040605P | 2005-10-26 | 2005-10-26 | |
| US60/730,406 | 2005-10-26 | ||
| PCT/US2006/042177 WO2007050975A2 (en) | 2005-10-26 | 2006-10-26 | Hydrophilic vehicle-based dual controlled release matrix system as capsule fill |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013133677A Division JP2013216680A (ja) | 2005-10-26 | 2013-06-26 | 親水性ベヒクルに基づく二重制御された放出マトリクスシステム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009513669A JP2009513669A (ja) | 2009-04-02 |
| JP2009513669A5 true JP2009513669A5 (enExample) | 2009-12-17 |
| JP5406530B2 JP5406530B2 (ja) | 2014-02-05 |
Family
ID=37801480
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008538048A Expired - Fee Related JP5406530B2 (ja) | 2005-10-26 | 2006-10-26 | 親水性ベヒクルに基づく二重制御された放出マトリクスシステム |
| JP2013133677A Pending JP2013216680A (ja) | 2005-10-26 | 2013-06-26 | 親水性ベヒクルに基づく二重制御された放出マトリクスシステム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013133677A Pending JP2013216680A (ja) | 2005-10-26 | 2013-06-26 | 親水性ベヒクルに基づく二重制御された放出マトリクスシステム |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8333989B2 (enExample) |
| EP (1) | EP1959935A2 (enExample) |
| JP (2) | JP5406530B2 (enExample) |
| CN (1) | CN101360485B (enExample) |
| CA (1) | CA2627292C (enExample) |
| WO (1) | WO2007050975A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2498207C (en) * | 2002-09-11 | 2012-03-13 | Elan Pharma International Ltd. | Gel-stabilized nanoparticulate active agent compositions |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| SI1993559T1 (sl) | 2006-02-03 | 2017-01-31 | Opko Renal, Llc | Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3 |
| DK3357496T3 (da) | 2006-06-21 | 2020-05-11 | Opko Ireland Global Holdings Ltd | Terapi ved brug af vitamin d-repletteringsmiddel og vitamin d-hormonsubstitutionsmiddel |
| PT2148661E (pt) | 2007-04-25 | 2013-03-06 | Proventiv Therapeutics Llc | Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso |
| PT2148684E (pt) | 2007-04-25 | 2013-04-19 | Cytochroma Inc | Método de tratamento para a insuficiência e deficiência de vitamina d |
| ES3047207T3 (en) | 2007-04-25 | 2025-12-03 | Opko Renal Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
| CA2687979C (en) | 2007-05-25 | 2017-07-04 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of risperidone compounds |
| CN106853250A (zh) | 2008-04-02 | 2017-06-16 | 赛特克罗公司 | 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒 |
| CN101491549B (zh) * | 2009-02-23 | 2011-08-03 | 四川珍珠制药有限公司 | 一种中药软胶囊及其制备方法 |
| CN101485707B (zh) * | 2009-02-23 | 2011-05-18 | 四川珍珠制药有限公司 | 一种灵丹草软胶囊及其制备方法 |
| US11672809B2 (en) | 2010-03-29 | 2023-06-13 | Eirgen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| US20150250750A1 (en) * | 2012-10-16 | 2015-09-10 | Wockhardt Limited | Pharmaceutical compostions of diclofenac or salts thereof |
| WO2014060857A1 (en) * | 2012-10-19 | 2014-04-24 | Wockhardt Limited | Pharmaceutical compositions of diclofenac or salts thereof |
| US10420729B2 (en) * | 2013-03-15 | 2019-09-24 | R.P. Scherer Technologies, Llc | Abuse resistant capsule |
| US20140271837A1 (en) * | 2013-03-15 | 2014-09-18 | Warner Chilcott Company, Llc | Pharmaceutical soft gelatin capsule dosage form |
| MX364440B (es) * | 2013-03-15 | 2019-04-26 | Warner Chilcott Co Llc | Forma de dosis farmacéutica de cápsula de gelatina blanda con goma guar modificada. |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| CA2919892C (en) | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| EP3501510B1 (en) | 2014-02-28 | 2020-07-01 | Banner Life Sciences LLC | Controlled release enteric soft capsules of fumarate esters |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| US10772842B2 (en) | 2015-01-09 | 2020-09-15 | Patheon Softgels Inc. | Abuse-deterrent opioids |
| US10182992B2 (en) | 2014-04-07 | 2019-01-22 | Patheon Softgels Inc. | Abuse-deterrent controlled release formulations |
| DK3169315T3 (da) | 2014-07-17 | 2020-08-10 | Pharmaceutical Manufacturing Res Services In | Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| WO2016140933A2 (en) * | 2015-03-02 | 2016-09-09 | Bionpharma Healthcare Llc | Immediate release soluble ibuprofen compositions |
| WO2017182237A1 (en) | 2016-03-28 | 2017-10-26 | Opko Ireland Global Holdings, Limited | Methods of vitamin d treatment |
| EP3573659A1 (en) * | 2017-01-24 | 2019-12-04 | Société des Produits Nestlé S.A. | Compositions comprising anti-fel d1 antibodies and methods for reducing at least one symptom of human allergy to cats |
| WO2021142062A1 (en) | 2020-01-10 | 2021-07-15 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| CN116367864A (zh) * | 2020-10-16 | 2023-06-30 | R·P·谢勒技术有限公司 | 控释填料组合物和含有该组合物的胶囊 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3947600A (en) * | 1973-10-12 | 1976-03-30 | General Foods Corporation | Dipeptide sweetening of comestibles |
| US4708834A (en) * | 1986-05-01 | 1987-11-24 | Pharmacaps, Inc. | Preparation of gelatin-encapsulated controlled release composition |
| GB2230440B (en) * | 1989-02-09 | 1993-05-19 | Sandoz Ltd | Novel cyclosporin galenic forms |
| JPH0717498B2 (ja) * | 1989-05-31 | 1995-03-01 | 興和株式会社 | 鎮咳去痰ソフトカプセル剤 |
| CA2017916C (en) * | 1989-06-07 | 1999-02-02 | Minoru Aoki | Etoposide preparations |
| ATE170745T1 (de) | 1991-04-08 | 1998-09-15 | Nippon Shinyaku Co Ltd | Kapsel mit langzeitwirkung fuer die adhäsion im gastrointestinaltrakt |
| US5505961A (en) * | 1993-08-05 | 1996-04-09 | R. P. Scherer Corporation | Gelatin capsules containing a highly concentrated acetaminophen solution |
| GB9322314D0 (en) | 1993-10-29 | 1993-12-15 | Scherer Ltd R P | Foam generating capsules |
| CA2181241C (en) * | 1994-01-24 | 2000-04-25 | Dadi Jamshed Dhabhar | Process for solubilizing difficultly soluble pharmaceutical actives |
| US5447729A (en) | 1994-04-07 | 1995-09-05 | Pharmavene, Inc. | Multilamellar drug delivery systems |
| US5641512A (en) * | 1995-03-29 | 1997-06-24 | The Procter & Gamble Company | Soft gelatin capsule compositions |
| FR2748209B1 (fr) | 1996-05-06 | 1998-06-05 | Adir | Composition pharmaceutique a base de matrices lipophiles stabilisees pour la liberation controlee de principes actifs |
| US6027746A (en) | 1997-04-23 | 2000-02-22 | Warner-Lambert Company | Chewable soft gelatin-encapsulated pharmaceutical adsorbates |
| BE1011363A3 (fr) * | 1997-09-11 | 1999-08-03 | Smb Technology | Capsules semi-solides autoemulsionnables matricielles a action prolongee. |
| GB2331458B (en) | 1997-11-21 | 2002-07-31 | Gursharan Singh Moonga | Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine |
| AU2117399A (en) * | 1998-01-20 | 1999-08-02 | Applied Analytical Industries, Inc. | Oral liquid compositions |
| US6365180B1 (en) * | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
| FR2782006B1 (fr) | 1998-08-07 | 2002-04-19 | Gattefosse Ets Sa | Composition a liberation prolongee apte a former une micro-emulsion |
| US6251426B1 (en) * | 1999-09-02 | 2001-06-26 | Banner Pharmacaps, Inc. | Ibuprofen-containing softgels |
| AU7716100A (en) * | 1999-09-27 | 2001-04-30 | American Cyanamid Company | Pharmaceutical carrier formulation |
| CA2359945C (en) | 1999-11-12 | 2011-04-26 | Abbott Laboratories | Inhibitors of crystallization in a solid dispersion |
| KR20010101122A (ko) * | 1999-12-20 | 2001-11-14 | 겜마 아키라 | 피부외용제 |
| US6491950B1 (en) | 2000-08-07 | 2002-12-10 | Kos Pharmaceuticals, Inc. | Controlled release pharmaceutical composition |
| US6524615B2 (en) | 2001-02-21 | 2003-02-25 | Kos Pharmaceuticals, Incorporated | Controlled release pharmaceutical composition |
| US20030105141A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
| JP2003055254A (ja) * | 2001-08-17 | 2003-02-26 | Toyo Capsule Kk | 経口投与用シクロスポリン製剤 |
| US7029698B2 (en) * | 2001-11-21 | 2006-04-18 | R.P. Scherer Technologies, Inc. | Acetaminophen compositions |
| MXPA04006875A (es) * | 2002-01-18 | 2004-12-06 | Control Delivery Sys Inc | Sistema de gel polimerico para suministro controlado de cofarmacos. |
| IL164163A0 (en) * | 2002-04-09 | 2005-12-18 | Pharmacia Corp | Process for preparing a finely self-emulsifiable pharmaceutical composition |
| FR2838349B1 (fr) * | 2002-04-15 | 2004-06-25 | Laurence Paris | Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication |
| US20040033257A1 (en) * | 2002-05-30 | 2004-02-19 | Strides Inc. | Pharmaceutical formulation in a drug delivery system and process for preparing the same |
| US7399488B2 (en) | 2002-07-05 | 2008-07-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
| DK1545475T3 (da) | 2002-10-01 | 2014-07-28 | Banner Pharmacaps Inc | Enterisk sammensætning til fremstillingen af blød kapselvæg |
| EP1653931A2 (en) | 2003-07-17 | 2006-05-10 | Banner Pharmacaps, Inc. | Controlled release preparations |
| US20050096365A1 (en) * | 2003-11-03 | 2005-05-05 | David Fikstad | Pharmaceutical compositions with synchronized solubilizer release |
| JP2007517884A (ja) | 2004-01-09 | 2007-07-05 | ワイス | 医薬組成物用のマイクロエマルジョン |
| CA2610465A1 (en) * | 2005-06-03 | 2006-12-14 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same |
-
2006
- 2006-10-26 CN CN2006800457275A patent/CN101360485B/zh not_active Expired - Fee Related
- 2006-10-26 WO PCT/US2006/042177 patent/WO2007050975A2/en not_active Ceased
- 2006-10-26 US US11/553,356 patent/US8333989B2/en not_active Expired - Fee Related
- 2006-10-26 EP EP06826983A patent/EP1959935A2/en not_active Withdrawn
- 2006-10-26 CA CA2627292A patent/CA2627292C/en not_active Expired - Fee Related
- 2006-10-26 JP JP2008538048A patent/JP5406530B2/ja not_active Expired - Fee Related
-
2013
- 2013-06-26 JP JP2013133677A patent/JP2013216680A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009513669A5 (enExample) | ||
| JP2009513657A5 (enExample) | ||
| JP4526384B2 (ja) | カンナビス活性成分の投与のためのフィルム型粘着性投与形態 | |
| Gilhotra et al. | A clinical perspective on mucoadhesive buccal drug delivery systems | |
| RU2408368C2 (ru) | Препараты соли бупропиона с модифицированным высвобождением | |
| CA2627292C (en) | Hydrophilic vehicle-based dual controlled release matrix system | |
| KR101234940B1 (ko) | 안정한 서방출형의 경구 투여용 조성물 | |
| JP7602324B2 (ja) | 重水素化ドンペリドン組成物、方法、及び調製 | |
| JP2013216681A (ja) | カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム | |
| JP2006514058A (ja) | 薬物の経口投与用の急速溶解フィルム | |
| JP2007522248A (ja) | てんかんおよび他のｃｎｓ障害の処置のための、ｎｍｄａレセプターアンタゴニストと抗てんかん薬との組み合わせ | |
| Gijare et al. | Orodispersible films: a systematic patent review | |
| JP2006515299A5 (enExample) | ||
| CN102821754A (zh) | 多层熔融挤出膜 | |
| KR20140121394A (ko) | 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합 | |
| Datir | Recent advances in mucoadhesive buccal drug delivery system and its marketed scope and opportunities | |
| JP2008532967A5 (enExample) | ||
| Chwieduk et al. | Fentanyl sublingual: in breakthrough pain in opioid-tolerant adults with cancer | |
| EP2853262B1 (en) | Treatment of sunburn using analgesics and antihistamines | |
| KR20050021003A (ko) | 대마 활성 성분의 투여용 필름 형상의 점막접착성 투여 제형 | |
| US6174899B1 (en) | Orally administered analgesic composition comprising myfadol | |
| HK40064919A (en) | Deuterated domperidone compositions and methods for therapy of disorders | |
| Mercadante | Opioid combination for cancer pain | |
| CN101658521A (zh) | 一种对乙酰氨基酚、伪麻黄碱和氯苯那敏的复方缓释制剂 | |
| Vocci | Recent Advances in Drug Development |